Press releases

All press releases Regulatory

Regulatory press release 2025-10-10

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2026

Regulatory press release 2025-10-08

Xspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval

Regulatory press release 2025-09-30

New number of shares and votes in Xspray Pharma after new share issue

Regulatory press release 2025-09-11

Xspray’s rights issue oversubscribed – over-allotment issue increased and fully utilized

Regulatory press release 2025-08-26

First day of trading in subscription rights and BTAs moved to August 27

Regulatory press release 2025-08-25

Xspray publishes disclosure document regarding rights issue

Regulatory press release 2025-08-25

Xspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue

Regulatory press release 2025-08-15

Interim Report Second Quarter 2025

Regulatory press release 2025-08-15

Xspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing

Regulatory press release 2025-08-12

Xspray Pharma signs license agreement with Handa Therapeutics – to receive up to double-digit royalty on Handa’s net proceeds

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe